ABSTRACT
In this era of passion to look beautiful, various new technologies are emerging to enhance and improve the physical appearance of people. Botox is emerging as one such popular treatment to improve various facial anomalies. Minimally invasive treatment can be done by botox, which can expand our therapeutic options for the benefit of our patients. The aim of this article is to elaborate the healing aspect of this toxin, i.e., botox.

Keywords: Botulinum toxin, Bruxism, Gummy smile, Hypertrophy.

INTRODUCTION
Many of us think of botox primarily as a cosmetic treatment for lines and wrinkles on the face, whereas botox, a botulinum toxin derivative, has a long history of therapeutic uses. Today, botox is the hottest name in the field of cosmetic and esthetic industry. Botox and dermal fillers are well known for their esthetic results in terms of smooth skin and replacing lost volume in face, especially the oral and perioral areas. There are many innovative, minimally invasive uses for botox in dentistry. Most of the dentists are not aware of these other considerable therapeutic benefits of botox in dental treatment, which include temporomandibular joint disorders, bruxism, oromandibular dystonia (OMD), mandibular spasm, dental implant and surgery, gummy smile, and masseteric hypertrophy.

HISTORY
In the nineteenth century, Justinus Kerner described botulinum toxin as a “sausage poison” and “fatty poison” (from Latin botulus meaning “sausage”), because the bacterium that produces the toxin often caused poisoning by growing in improperly handled or improperly prepared meat products. The term “Botulism” was coined by Kerner, a physician, who first recognized the therapeutic use of botulinum toxin. In 1897, Emile van Ermengem isolated the botulin toxin from a bacterium, and named it Clostridium botulinum. Snipe and Sommer purified the toxin for the first time in 1928. In 1949, Burgen’s group experimentally discovered that botulinum toxin blocks neuromuscular transmission through decreased acetylcholine release. It can be absorbed from the eyes, mucous membranes, respiratory tract, or nonintact skin. Botulinum toxin type I (Allergan’s botox), has both therapeutic and cosmetic applications. Since 20 years, botox got approval from the Food and Drug Administration (FDA) for therapeutic treatments of eye muscle problems (in 1989), neck problems (in 2000), and excessive sweating (in 2004). At present, it is being investigated for treating other medical conditions. Botox neurotoxin was accepted by the FDA in March 2010 for the treatment of increased muscle stiffness in the finger muscles, elbow, and wrist in people 18 years and older with upper limb spasticity.

DOSAGE AND MECHANISM OF ACTION
Commercially, two main types of botox are available: Botulinum toxin type I and botulinum toxin type II. Further, three forms of botulinum toxin type I, i.e., botox, Dysport, and Xeomin are available commercially for various cosmetic and medical procedures.

Botox can cause partial chemical denervation of the muscle, which results in localized reduction in muscle activity. Type I form of botulinum toxin inhibits the release of acetylcholine on cholinergic nerve endings of motor nerves, as it avoids the vesicle where the acetylcholine is stored from binding to the membrane where the neurotransmitter can be released (Figs 1A and B). Botulinum toxin achieves this effect by its endopeptidase activity against SNARE proteins, which are 25-kD synaptosomal associated proteins that are required for the docking of the acetylcholine vesicle to the presynaptic membrane (Fig. 2). Thus, botulinum toxin type I inhibits the release of acetylcholine by the neuron. This effectively weakens the muscle for a period of 3 to 4 months. It was suggested that when botulinum toxin was used for the treatment of neuromuscular disorders, particularly
focal dystonias and spastic conditions, patients reported a marked analgesic benefit. Initially, this benefit was believed to be due to the direct muscle relaxation effect of botulinum toxin; however, various observations have suggested that botulinum toxin may exert an independent action on peripheral nociceptors by blocking exocytosis of such neurotransmitters as substance P, glutamate, and calcitonin gene–related peptide. In addition, botulinum toxin does not cross the blood–brain barrier, and it is inactivated during its retrograde axonal transport; the effect is believed to be in the first-order sensory nerve and not more centrally.12

It can be used as an adjunct to oral medication or as a sole therapy. Botulinum toxin A is kept frozen (2–40°C) in a vial until it is mixed with 4 mL of 0.9% preservative-free normal saline solution, which makes it ready for use within 4 hours. Each vial of botox contains: 100 U of Clostridium botulinum type I neurotoxin complex, 0.9 mg of sodium chloride without a preservative in a sterile vacuum-dried form, and 0.5 mg of human albumin. The syringe preferred is a calibrated 1.0-mL tuberculin syringe, and the needle selected for injection usually is between 26 and 30 gauge.13

Mouse unit is the expression of potency of botox. A unit of botox is defined as the LD50 for a colony of 20 gm Swiss-Webster mice,13 extrapolated to the 70 kg human, and each 0.1 mL contain 2.5 U of botox. Botox is provided in small vials containing 500 U or 100 U in humans; lethal dose of botox is not prescribed. Although it has been estimated to be about 3000 U,14,15 the maximum permissible dose of botox for dental applications at an injection session is about 80 to 100 U. It determines that 30 vials of botox will have to be injected before potentially destructive results. The cleaning of skin has to done with a chlorhexidine/alcohol/betadine swab, before injecting botox into the joint and/or muscle and/or skin. Before injection, aspiration is recommended to avoid involuntary deposition of toxin into the facial arteries. Closed to immediate results can be achieved in one short appointment with the use of botulinum toxin A, but the results obtained are not permanent and stay for 6 months, with an average range of 4 to 8 months.16 It has to be repeated 2 to 3 times a year depending upon the decrease in its effect. The therapeutic effects of botulinum toxin A start first appearing in 1 to 3 days, show peak level in 1 to 4 weeks, and start decreasing after 3 to 4 months.17

In a study, 3 to 4 weeks after a single injection of botulinum toxin A in mice, there is sprouting of new processes along the nerve axon, with formation of multiple synapses with the muscle and upregulation of the muscle nicotinic receptors. The original synaptic connection is restored after the neuronal sprouts undergo regression, with restoration of original neuromuscular junction.18,19 Therefore, cost factor increases due to repeated administration of botulinum toxin injections 2 to 3 times a year. Injections are spaced out for a minimum of 3 months to minimize the risk of antibody formation to the protein, which would prevent botox from working the subsequent time.3

Figs 1A and B: (A) Botox binding to nerve ending; and (B) blocking release of acetylcholine

Fig. 2: Endopeptidase activity against SNARe proteins
APPLICATIONS OF BOTOX

Botox can be used in the treatment of various problems, which includes temporomandibular disorders (TMD), massectric hypertrophy, hemifacial spasm, myofacial pain, bruxism, trismus, sialorrhea, retraining muscles during orthodontic therapy; in patients with a very strong musculature; training the patient to get used to new dentures, especially in patients with strong irregular muscle contractions and jaw line contouring by injecting into masseter muscle, thus weakening it and resulting in a more tapered jaw line.

Temporomandibular Joint Disorders

Temporomandibular disorder is a term used to describe a number of diseases affecting masticatory function, which may include true pathology of the temporomandibular joint as well as masticatory muscle dysfunction. The TMD is apparent with headache, neck pain, facial pain, periauricular pain, joint sounds, and/or decreased jaw excursion. The majority of TMD cases include a myogenic component, and muscular spasticity secondary to bruxism, external stressors, OMD, and psychomotor behaviors are common etiologic factors of TMD.

Excessive biting forces causing TMD have conventionally been treated with occlusal adjustments, intraoral appliances, dental restoration, and/or surgery. These techniques are expensive, invasive, and irreversible for the majority of patients.

The techniques currently in use for conservative, esthetic restorations may not be able to stand with the parafunctional forces continually applied by some patients. Thus, these treatment options are not considered as ideal for all patients, so muscular relaxation with botulinum toxin A can be a viable alternative. When a muscle relaxant is used with the muscles of mastication, this clenching reflex can be reduced or eliminated. Because a very small percentage of available force is required to masticate food, a slight relaxation of muscle function reduces bruxing and is usually insufficient to affect chewing and swallowing.

Temporomandibular Disorders Treatment Protocol

Treatment starts with a lower dose, because it is always possible to quantify up to a higher dose; if necessary, the pain of temporals component is treated with bilateral injections of 7.5 U into the anterior vertical fibers of each temporals muscle; 2.5 U dose can be given into the middle and posterior third of the temporals muscles in more severe cases. Relief for pain for the tendon of temporals is achieved with many injections of 2.5 U equidistantly spaced in the temple area outside the orbital rim. The massetter component of pain is treated with 5 U injected into the belly of the massetter below an imaginary line joining the tragus of the ear and the corner of the mouth.

Several case reports support the efficacy of botox treatment for TMD. Freund et al conducted a large open-label trial with 46 patients suffering from TMD and found that 150 U injections of botox to the temporalis and massetter muscles significantly decreased pain and tenderness and improved function and mouth opening. Tan and Jankovic conducted a long-term open-label trial on 18 patients with a history of severe bruxism. Botox injections can be given to the massetter muscle (mean dose: 61.7 U/side; range 25–100 U), yielding a total duration of therapeutic response of 19 weeks. Lee et al did a small open-label trial study to find out the effect of botox on pain due to TMD in six patients with limited mouth opening. All patients showed clinical remission of pain symptoms without any adverse effects during the 5 to 12 months follow-up period.

Bruxism

Bruxism is a repetitive jaw-muscle activity characterized by clenching or grinding of the teeth and/or by bracing or thrusting of the mandible. It shows two distinct circadian manifestations: It can occur during wakefulness (indicated as awake bruxism) and during sleep (indicated as sleep bruxism). Botulinum neurotoxin has also shown promise in alleviating the symptomatology of bruxism. Excessive forces created by parafunctional clenching impede healing and reattachment of gum and bone in the mouth after trauma. Botulinum toxin type I restricts the muscle contraction; this results in decreasing the clenching intensity. This will allow traumatized tissue to heal. Because parafunctional clenching can contribute toward the periodontal trauma, botulinum toxin type I can restrict clenching before and after periodontal surgery to improve the healing. Further, in this regard, the use of a splint is not recommended because the teeth should be functional during the healing phase, so botulinum toxin can also acts as a pharmaceutical splint. One of the earliest reports on the use of botulinum toxin type I for bruxism was by Van Zandijcke and Marchau, who described the successful treatment of a brain-injured patient with severe bruxism with 100 U of a botulinum toxin type I injection to the temporalis and massetter muscles.

Oromandibular Dystonia

It is a movement disorder, i.e., characterized by involuntary spasms and muscle contractions. It is apparent as distorted function and oral positioning, resulting in
difficulty in eating, swallowing, and speaking. Although it is a neurologic disorder, it is included as a subset of TMD because of its involvement of the masticatory apparatus.31 Most of the reported literature on OMD has been open-label studies, but all have reported improvement with botulinum toxin injections.32-36 The largest study to date was a prospective open-label study conducted by Tan and Jankovic36 that treated 162 patients with OMD over a 10-year period. Increase in the function for speaking and chewing was found in 67.9% of the patients, and clinical improvement was found to be 16.4 ± 7.1 weeks.35

**Mandibular Spasm**

It shows a condition in which closing musculature of mandible remains in spasm or semicontracted stage, which results in decrease in mouth opening. This type of muscular spasm causes restrictions in dental treatment and limits completion of the basic needs of oral hygiene, which is necessary to prevent many oral diseases. Botox treatment decreases the effect of spastic muscles or hyperfunctioning muscles that help in improving mouth opening and function. Botox treatment also effectively decreases tenderness and pain to palpation. Several case reports have been published, describing the effectiveness of botox in patients with hemimasticatory spasm, which includes studies conducted by Cersósimo et al,37 Auger et al,38 Kim et al,39 and Kim et al,40 where all the patients responded positively to botox injections.

**Dental Implant and Surgery**

Implant patients will benefit from presurgical botox treatment. Overloading of the muscles of mastication can prevent or impede osseointegration of implants and/or fracture callus formation.41,42 The muscular relaxation gained with botulinum toxin type I can be therapeutically beneficial for fracture healing in a more stable environment and also for dental implants, by allowing implants better unimpeded osseointegration.

Kayikçıoğlu et al42 did a small open-label study to find out the use of botulinum toxin type I as an adjunct to zygomatic fracture fixation surgery, in order to reduce the number of fixation sites and to prevent dislocation of the zygomatic bone. Zygomatic bone fractures of five male patients were injected with 100 U of botulinum toxin type I at the fractured site of masseter muscle; 12 to 48 hours after the injection, patients were then operated and electromyograph confirmation of muscle denervation was done. The temporary paralysis of the masseter muscles allowed for fewer miniplate and/or microplate insertions in all patients and resulted in no complications related to either the botulinum toxin injections or surgical procedures. Kayikçıoğlu group42 also found similar benefits of adjunct botulinum toxin treatment for surgical reduction of mandibular and condylar bone fractures.

**Gummy Smile**

The display of excessive gingival tissue in the maxilla upon smiling or the “gummy smile” is both an oral hygiene and esthetic issue with no simple remedy. Several surgical techniques have been reported in the literature for the correction of hyperfunctional upper lip elevator muscles, such as Rubinstein and Kostianovsky, Miskinyar, and Rees and LaTrenta techniques. However, routinely, they are not used to treat gummy smiles. Surgical corrections for skeletal vertical maxillary excess and gingivectomies for delayed passive dental eruption with excessive gingival display are corrected by the Lefort 1 maxillary osteotomies with impaction. Carefully titrated doses in small quantity can make these muscles proportionately weakened with botox, which will result in decreased exposure of the upper gums during smiling. Polo43 carried out a study in five patients with excessive gingival display due to hyperactive upper lip elevator muscles who were treated with botox under electromyographic guidance. Patients received one 0.25 U injection per muscle bilaterally into the levator labii superioris, superiori slabii alaeque nasi, and at the overlap areas of the levator labii superioris and zygomaticus minor muscles. All patients were satisfied with the obtained results. The effective increase in the upper lip length upon smiling averaged 124.2%; the duration of effect ranged from 3 to 6 months, and no adverse effects were reported or observed.

**Masseteric Hypertrophy**

Patients who are chronic jaw clenchers frequently present with masseteric hypertrophy.44 The size of these muscles is increased, and it is evident in the facial profile of patients, which is often altered, e.g., the jaw can appear misshapen and swollen. The commonly used treatment for this is the surgical resection, which may result in substantial contracture. In several small but well-documented clinical trials by Al-Ahmad and Al-Qudah,45 Mandel and Tharakar,46 and Rijsdijk et al,47 injection of small aliquots of botox into the masseter muscles resulted in a sustained reduction of masseter hyperactivity.

Besides these applications, botox can be used in hemifacial spasm, myofascial pain, trismus, sialorrhea, migraine cluster headache, retraining muscles during orthodontic therapy; in patients with a very strong musculature; training the patient to get used to new dentures, especially in patients with strong irregular
muscle contractions and jaw line contouring by injecting into masseter muscle, thus weakening it and resulting in a more tapered jaw line.

CONTRAINDICATIONS
The relative contraindications include pregnancy, lactation, neuromuscular diseases (myasthenia gravis, Eton-Lambert syndrome), motoneuron diseases, concurrent usage of aminoglycosides, and sensitivity to toxin.

ADVERSE EFFECTS
Botulinum toxin in oromandibular disorders include facial nerve palsy, pain at the injection site, flu-like symptoms, nontargeted muscle weakness, dysphagia, and hematoma. These complications are generally transient and resolve within a couple of weeks.

CONCLUSION
Undoubtedly, botox, a minimally invasive and attractive treatment, is the best option in comparison to surgical alternatives. However, there is much more still to be discovered to allow its routine use in dental clinics for various problems. There are still many conditions which require FDA approval to be treated by botulinum toxin. Therefore, minimally invasive botox will surely take dental profession one step ahead.

REFERENCES
25. Gobel H, Heinze A, Heinze-Kuhn K. Botulinum toxin A is effective in cases of oromandibular dysfunction even if previous bite splint therapy has proved unsuccessful. Cephalalgia 2001 May;21(4):514-515.


